Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Clene Inc.

Current price
0.31 USD -0.038 USD (-10.92%)
Last closed 0.33 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 45 284 420 USD
Yield for 12 month -69.90 %
21.11.2021 - 28.11.2021

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Address: 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

+654 000 USD

Last Year

+473 000 USD

Current Quarter

+170 000 USD

Last Quarter

+108 000 USD

Current Year

-1 172 000 USD

Last Year

+447 000 USD

Current Quarter

-290 000 USD

Last Quarter

+96 000 USD

Key Figures CLNN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -38 835 000 USD
Operating Margin TTM -5841.18 %
PE Ratio
Return On Assets TTM -52.33 %
PEG Ratio
Return On Equity TTM -595.47 %
Wall Street Target Price 5 USD
Revenue TTM 654 000 USD
Book Value 0.1 USD
Revenue Per Share TTM 0.006 USD
Dividend Share
Quarterly Revenue Growth YOY -27.4 %
Dividend Yield
Gross Profit TTM 447 000 USD
Earnings Share -0.47 USD
Diluted Eps TTM -0.47 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY 61.4 %
Profit Margin

Dividend Analytics CLNN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLNN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:1
Payout Ratio
Last Split Date 31.12.2020
Dividend Date

Stock Valuation CLNN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 65.9225
Price Sales TTM 70.6365
Enterprise Value EBITDA -0.997
Price Book MRQ 3.4318

Financials CLNN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CLNN

For 52 weeks

0.25 USD 1.09 USD
50 Day MA 0.42 USD
Shares Short Prior Month 262 478
200 Day MA 0.52 USD
Short Ratio 0.25
Shares Short 162 889
Short Percent 0.17 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics